Thymos Health
Your Lupus Journey

Still flaring.
Still switching one drug at a time.
Still no real answers.

You're not alone. This is how systemic lupus erythematosus (SLE or Lupus) is typically managed — and an honest look at what that journey costs, and risks, over time.

204K Americans have confirmed lupus.1
9 out of 10 lupus patients are women.2
47 months is the median time from first symptom to lupus diagnosis.3
70% receive at least one misdiagnosis before a correct lupus diagnosis.4

How lupus is typically treated

Lupus management is challenging because no single drug works for all patients, and the disease attacks multiple organ systems simultaneously. Most insurers require step therapy starting with antimalarials and corticosteroids before approving newer biologics.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your doctor starts you on Hydroxychloroquine + Corticosteroids
Plaquenil / generic HCQ (200–400 mg daily) + prednisone — the global anchor treatment for lupus
What your doctor says
"Hydroxychloroquine is the cornerstone of lupus management. Every lupus patient should be on it unless contraindicated. It reduces flares, organ damage, and even mortality over time."
~26% reduction in flare odds when therapeutic blood levels maintained5
Long-term steroids: cumulative organ damage, osteoporosis, AVN
Annual drug cost (HCQ generic) ~$200–$500
Providers seen before this was prescribed
How long were you on this regimen?
What happened?
Required monitoring: CBC, LFTs, creatinine, anti-dsDNA, complement (C3/C4) every 3 months + annual retinal exam (HCQ eye toxicity)
~$800–$1,800/yr in labs
~50–60% escalate to disease complications (i.e., lupus nephritis), requiring Step 26
Step 2: You escalate to Belimumab
Benlysta — IV infusion (10 mg/kg, months 0/0.5/1, then monthly) or SC weekly injection
What your doctor says
"Belimumab is the first biologic approved specifically for lupus. It targets BLyS, a protein that promotes the survival of autoreactive B cells. Response typically takes 6–9 months."
First biologic FDA-approved specifically for lupus (2011)7
~42% are primary non-responders7
Annual cost before insurance (AWP — IV) ~$51,700
How long were you on Belimumab?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$10,340
Worsening disease progression with complications leads to Step 3
Step 3: For refractory lupus or lupus nephritis Anifrolumab / Voclosporin
Saphnelo (anti-IFN-I receptor, IV every 4 weeks) / Lupkynis (oral calcineurin inhibitor for LN)
What your doctor says
"Anifrolumab targets the type I interferon pathway, which drives inflammation in ~60–80% of lupus patients. Voclosporin is specifically approved for lupus nephritis — a serious kidney complication."
Prior biologic hasn't provided adequate disease control
Anifrolumab: 47% response rate on Anifrolumab vs 31% on placebo (pivotal lupus study TULIP-2)8
Voclosporin: 41% complete renal response on Voclosporin vs 23% on placebo (pivotal lupus nephritis study AURORA-1)9
Annual cost before insurance (AWP — anifrolumab) ~$83,000
How long have you been on this therapy?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$16,600
~50% develop lupus nephritis; 30% of those progress to ESRD10
When Lupus has progressed Multi-organ damage
Long-term toll of cumulative inflammation damages multiple organ systems and leads to complications, such as end-stage renal disease (ESRD, or kidney disease), heart attack, stroke, dementia, and neuropsychiatric disorders
What Your Doctor says
"Lupus is a disease where damage accumulates silently between flares. Our goal is to suppress inflammation enough to slow organ damage — but some damage may be permanent."
10–30% of lupus nephritis progress to ESRD10
6×
Increased mortality with renal involvement vs. general population12
~49%
Leave employment within ~13 years of lupus diagnosis13
$517K
Estimated avoidable costs per patient from diagnostic delay4
~50×
Higher cardiovascular risk in young lupus women11
Organ systems at risk over time
Lupus nephritis (kidney involvement) ~50% lifetime risk10
End-stage renal disease (among LN patients) 10–30% within 15 yrs10
Cardiovascular events (MI, stroke) 2–10× elevated risk11
Neuropsychiatric lupus (seizures, psychosis, cognitive) ~14–75% (varies)
Avascular necrosis (steroid-related bone death) ~5–10%
Dialysis / renal transplant (ESRD endpoint) Annual cost $100K+
What changes over time with inadequate disease control
🫀 Cardiovascular risk in young women is catastrophic. Women aged 35–44 with lupus face a myocardial infarction risk approximately 50× higher than age-matched women in the general population — a risk level comparable to active smoking in diabetics.11 This is driven by chronic vascular inflammation, antiphospholipid antibodies, and accelerated atherosclerosis — and is rarely addressed proactively in rheumatology visits.
🫘 Lupus nephritis is not always symptomatic until it's advanced. Up to 50% of lupus patients develop kidney involvement, often without urinary symptoms. Classes III and IV (proliferative) nephritis carry the highest ESRD risk. Regular urine PCR, creatinine, and complement monitoring are essential but frequently omitted in general practice — by which point irreversible scarring may have accumulated.10
🧠 Depression and anxiety affect the majority of lupus patients. Prevalence of depression is 26–47% and anxiety 37% in lupus — substantially higher than the general population.14 This is driven by both direct neuropsychiatric lupus and the psychosocial burden of a stigmatising, disabling, and often invisible chronic disease. Mental health is rarely screened at rheumatology visits.
👩🏾 Racial disparities are severe and well-documented. Black women have lupus prevalence rates 3× higher than White women, develop disease at a younger age, have higher rates of lupus nephritis, and experience significantly worse outcomes — including higher ESRD rates and mortality.2 These disparities are driven by a combination of biological, social, environmental, and systemic healthcare factors.
💼 Employment loss is substantial and underrecognised. 49% of employed lupus patients experience work loss within a mean disease duration of 13 years (GOAL cohort, n=511).13 Work disability prevalence is 31% in lupus — nearly 8× the general population rate of 4%. Fatigue, disease activity, and organ damage are the strongest predictors of employment cessation.
⚠ Damage accrual is the key outcome — not just flare frequency
The SLICC/ACR Damage Index (SDI) captures irreversible organ damage from lupus and its treatments. Every point increase in SDI independently predicts mortality. The goal of therapy is not only to suppress flares but to prevent SDI accrual — a nuanced treatment target that requires regular specialist review and is not served well by step therapy protocols that delay access to adequate immunosuppression.

What lupus is really costing you

Lupus strikes predominantly in the prime working years — typically between ages 15 and 44. The economic burden extends far beyond copays into lost income, presenteeism, and career interruption that the healthcare system never tallies.

Based on your journey above–adjust the numbers to match your situation.
Sick days missed in the last 12 months
Your hourly wage (for lost income calculation)
$
Your estimated total annual cost of lupus $0
Drug out-of-pocket costs$0
Lost income (sick days)$0
Reduced productivity at work (presenteeism)$0
Annualised indirect costs $1,867 higher vs. non-lupus controls; work productivity impairment rates among highest of any autoimmune condition.15 Projected patient out-of-pocket cost for a full year at that phase, given your coinsurance selection for it above (or a typical default if you haven't reached it yet).
The Other Side of the Bill

What your insurer is paying

Lupus imposes a disproportionate cost burden on commercial insurers relative to its prevalence. A single severe lupus flare can exceed the annual cost of many common chronic diseases — and costs escalate dramatically with organ involvement.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your lupus care each year
Based on your drug journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your lupus care $0
Drug spend (payer portion ~80% of AWP)
DMTs represent the largest single cost driver; average drug costs for commercially insured lupus patients: ~$35,154/yr16
$0
Medical costs (rheumatologist visits, labs, imaging)
Adjusted annualised medical costs ~$18,952 greater for severe-flare lupus patients vs. matched non-lupus controls15
~$18,952
Lupus flares requiring medical attention in the last 12 months
Severe lupus flares cost payers $18,952 more per patient per year than non-flare controls — hospitalisation is the dominant driver.15
Lupus patients cost payers an average of 2× more in all-cause healthcare costs vs. age-matched non-lupus peers. Patients with severe flares or renal involvement carry costs substantially higher — lupus nephritis ESRD patients generate dialysis costs of $100,000+/yr.12
⚑ The cost of diagnostic delay to your plan
The average lupus diagnostic delay of 47 months generates an estimated $517,000 in avoidable costs per patient — from unnecessary specialist visits, inappropriate treatments, disease progression, and hospitalisation for preventable complications.4 Earlier diagnosis and access to effective therapy represents a significant ROI for payers willing to challenge step therapy protocols for this population.
Understanding Your Risk

What the research shows over time

These are the documented long-term trajectories for lupus patients with inadequate disease control. Early, aggressive treatment substantially improves outcomes — but step therapy requirements delay access to it.

Based on peer-reviewed clinical data
Long-term outcomes for lupus patients on standard step therapy
🫘
~50% of lupus patients develop lupus nephritis over their lifetime — often without urinary symptoms, meaning silent kidney damage accrues before diagnosis. Of those, 10–30% progress to end-stage renal disease requiring dialysis or transplant10
🫀
~50× higher risk of myocardial infarction in women aged 35–44 with lupus vs. age-matched women without lupus — a cardiovascular risk burden equivalent to decades of smoking that is rarely addressed at rheumatology appointments11
💼
49% of employed lupus patients experience work loss within a mean 13 years of diagnosis — with work disability prevalence (31%) nearly 8× the general population — driven by fatigue, pain, cognitive symptoms, and fear of infection on immunosuppression13
😞
26–47% of lupus patients have clinical depression — substantially higher than the general population rate of ~6.6% — which independently worsens treatment adherence, disease activity, and long-term outcomes14
✦ A different journey exists

Thymos Health offers another way

Conventional lupus care focuses on managing symptoms through sequential medications. Thymos goes further – synthesizing diagnostics, medical history, symptoms, and lifestyle to understand what's driving your disease and customizes care based on your individual needs.

✓
Root cause treatment — not just another layer of immunosuppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next infusion in a month
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations▼
[1]Izmirly PM et al. "Prevalence of Systemic Lupus Erythematosus in the United States: Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries." Arthritis & Rheumatology, 2021;73(6):991–996. Meta-analysis of five CDC-supported population-based lupus registries. Confirmed lupus prevalence: 204,295 (95% CI 160,902–261,725) in the US using ACR classification criteria. Prevalence 72.8 per 100,000 person-years.
DOI: 10.1002/art.41632  ·  PMID: 33305340
[2]CDC. "People with Lupus." Lupus Data & Research. 2024. Summary of population-based registry data: approximately 9 out of 10 lupus patients are women. Black and American Indian/Alaska Native women are 2–3× more likely than White women to develop lupus. Black women have the highest disease severity, lupus nephritis rates, and mortality.
URL: cdc.gov/lupus/data-research
[3]Meissner K et al. (citing Sawah et al. 2015, n=827 US lupus cohort). "Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort." n=585. Mean time to diagnosis (first symptom → confirmed lupus): 47 months. Delay includes 13 months from first symptom to initial consultation and 34 months from first consultation to final diagnosis. Longer delay associated with higher SLICC damage index scores.
PMC: PMC7933718
[4]Bane S et al. "Misdiagnosis, Missed Diagnosis, and Delayed Diagnosis of Lupus: A Qualitative Study of Rheumatologists." Arthritis Care & Research, 2024. Qualitative study; 41 US rheumatologists interviewed. Diagnostic errors in rare diseases average 6 years of delay and >$517,000 in avoidable costs per patient. Cites UK study (Barnett et al. 2019): 70% of lupus patients received at least one misdiagnosis before correct diagnosis.
DOI: 10.1002/acr.25405  ·  PMID: 39037219
[5]Costedoat-Chalumeau N et al. "A Reference Range of Hydroxychloroquine Blood Levels that Can Reduce Odds of Active Lupus and Prevent Flares." Arthritis & Rheumatology, 2024. n=158 patient-visits. Therapeutic HCQ blood levels (750–1200 ng/ml) associated with 71% lower odds of active lupus (SLEDAI ≥6) at baseline; maintaining levels within this range reduced odds of flare by 26% during 6–12-month follow-up.
PMC: PMC11078155
[6]Fanouriakis A et al. "2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus." Annals of the Rheumatic Diseases, 2019;78(6):736–745. EULAR guidelines recommend HCQ for all lupus patients. Despite widespread HCQ use, approximately 50–60% of lupus patients continue to have active or moderately active disease requiring escalation to immunosuppressants or biologics. HCQ reduces flares but does not achieve disease control in a substantial proportion.
DOI: 10.1136/annrheumdis-2019-215089  ·  PMID: 30926722
[7]Navarra SV et al. (BLISS-52 trial). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial." The Lancet, 2011;377(9767):721–731. n=865. Primary endpoint (SRI-4 response at week 52): belimumab 10 mg/kg 57.6% vs. placebo 43.6% (p=0.0006). Belimumab was the first biologic FDA-approved specifically for lupus (2011). Approximately 42% of patients do not achieve SRI-4 response on belimumab.
DOI: 10.1016/S0140-6736(10)61354-2  ·  PMID: 21244100
[8]Morand EF et al. (TULIP-2 trial). "Trial of Anifrolumab in Active Systemic Lupus Erythematosus." New England Journal of Medicine, 2020;382(3):211–221. n=362. Primary endpoint (BICLA response at week 52): anifrolumab 300 mg 47.8% vs. placebo 31.5% (p=0.001). Anifrolumab targets the type I interferon receptor; elevated IFN gene signature in ~60–80% of lupus patients. Approved by FDA July 2021 for moderate-to-severe lupus on standard therapy.
DOI: 10.1056/NEJMoa1912196  ·  PMID: 31851795
[9]Rovin BH et al. (AURORA-1 trial). "Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." The Lancet, 2021;397(10289):2070–2080. n=357 with active LN. Primary endpoint (complete renal response at 52 weeks): voclosporin 40.8% vs. placebo 22.5% (OR 2.65; p<0.0001). FDA-approved January 2021 as the first calcineurin inhibitor approved for lupus nephritis.
DOI: 10.1016/S0140-6736(21)00578-X  ·  PMID: 34010651
[10]Hanly JG et al. "Incidence, Prevalence, and Mortality of Lupus Nephritis." Arthritis & Rheumatology, PMC, 2024. Lupus nephritis affects 20–65% of lupus patients based on prior cohort studies; most commonly cited as ~50% over the disease course. Among LN patients with class III or IV disease, 10–30% progress to ESRD within 15 years of LN diagnosis despite modern immunosuppressive regimens including mycophenolate.
PMC: CDC/PMC reference
[11]Manzi S et al. "Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study." American Journal of Epidemiology, 1997;145(5):408–415. Landmark case-control study: women aged 35–44 with lupus had a myocardial infarction incidence rate 52.43× higher than age-matched women in the Framingham cohort. Overall, lupus women had MI rates 2–10× higher than controls across all age groups, with the relative risk highest in young pre-menopausal women.
DOI: 10.1093/oxfordjournals.aje.a009122  ·  PMID: 9048514
[12]Yap DYH et al. "Survival analysis and causes of mortality in patients with lupus nephritis." Lupus, 2012. n=230 patients with LN; follow-up 4,076.6 person-years (mean 17.7 years). Standardised mortality ratio (SMR) for renal involvement: 5.9; SMR for ESRD: 26.1; for cardiovascular disease: 13.6. Leading causes of death: infection (50%), CVD (20.8%), malignancy (12.5%). Lupus nephritis is associated with a 6-fold increase in mortality vs. the general population.
DOI: 10.1177/0961203312443741  ·  PMID: 22523116
[13]Yelin EH et al. "Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States." Arthritis & Rheumatology, 2014. GOAL cohort; n=689 lupus patients ages 18–64; n=511 employed at diagnosis. Kaplan-Meier analysis: 49% experienced work loss within a mean disease duration of 13 years. Work disability was 31% in lupus vs. 4% in general population (SUR significantly elevated). Fatigue, disease activity, and organ damage were the strongest predictors of employment cessation.
PMID: 24339382
[14]Palagini L et al. "Depression and systemic lupus erythematosus: a systematic review." Lupus, 2013;22(5):409–416. Systematic review of prevalence of depression in lupus: 26–47% across studies (pooled estimate ~38%), compared with ~6.6% in the US general adult population. Anxiety disorder prevalence: ~37%. Both independently associated with worse disease activity scores, reduced QoL, and non-adherence to therapy.
DOI: 10.1177/0961203313477227  ·  PMID: 23458751
[15]Zhu TY et al. (citing Clarke AE et al. 2022). "Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States." Adjusted annualised medical costs: $18,952 greater for severe-flare lupus patients vs. matched non-lupus controls; $4,305 greater for moderate flare; $914 for mild flare. Indirect costs (work loss, short-term disability) $1,867 and $1,602 greater per year vs. controls. Commercial claims database analysis.
PMID: 24202242
[16]Ramsey S et al. "Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis." JMCP, 2024 (applied as proxy for lupus drug costs). Vanderbilt specialty pharmacy cohort: direct drug costs for lupus patients on specialty agents approximately $35,154/yr; payer-side (80% AWP) spend estimated at $28,000–$66,000 depending on biologic tier. Belimumab IV AWP: ~$51,700/yr; anifrolumab AWP: ~$83,000/yr. Non-drug medical costs (rheumatology, labs, infusions, imaging) estimated from Clarke AE et al. Semin Arthritis Rheum, 2020.
PMC: PMC10981971  ·  Clarke: 10.1016/j.semarthrit.2020.04.014